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Up-regulation of a fibroblast growth factor binding protein in and extracellular matrix, and is released into the circula-
children with renal diseases. tion by nonconventional pathways during angiogenesis,
Background. Basic fibroblast growth factor (bFGF) is an tumor growth, and/or tissue injury/regeneration [1–6].angiogenic growth factor that is involved in renal growth and
For example, bFGF is released by Kaposi’s sarcoma (KS)the pathogenesis of renal diseases. We have detected high
cells [7] and is involved in the pathogenesis of KS lesionslevels of bFGF accumulated in the kidney of HIV-transgenic
mice and in children with HIV-associated renal diseases and the in HIV-infected patients [7, 8]. We have found high levels
hemolytic uremic syndrome (HUS). However, the mechanism of bFGF in the kidney and the circulation of HIV-trans-
modulating the activity of bFGF under these circumstances is genic (Tg) mice [9], HIV-infected children with renal
poorly understood. We carried out experiments to determine
disease [10], and children with the hemolytic uremic syn-whether a secreted binding protein (FGF-BP) that modulates
drome (HUS) [10, 11]. These findings suggest that bFGFthe activity of bFGF during the process of tumor growth was
expressed in pediatric kidneys and to define whether the ex- is released into the systemic circulation and renal intersti-
pression of FGF-BP was altered in pediatric renal diseases tium by injured endothelial and renal epithelial cells,
associated with high levels of bFGF. and that it may play a role in the pathogenesis of HUS
Methods. Immunohistochemistry and in situ hybridization and HIV nephropathy.studies were done in 41 renal sections from children with HIV
A characteristic finding of HIV-associated nephropa-nephropathies, HUS, other pediatric renal diseases, controls,
thy (HIVAN) is the presence of a combination of prolif-and fetal kidneys. Western blots and reverse transcriptase-
polymerase chain reaction studies were done in selected urine erative and sclerotic renal lesions, including focal or
samples and cultured renal cells. Recombinant FGF-BP was global glomerulosclerosis, microcystic tubular dilation
produced to study the mitogenic activity of FGF-BP in cultured with tubular degenerative changes, and interstitial fibro-human renal proximal tubular epithelial cells (RPTEcs).
sis leading to end-stage renal disease [12–15]. AlthoughResults. The expression of FGF-BP was up-regulated pre-
recent studies have suggested that HIV-1 may play adominately in renal tubular epithelial cells in children with
renal tubular injury, HIV-associated nephropathy (HIVAN), direct role in the pathogenesis of these renal lesions [9,
and HUS, and FGF-BP was secreted in the urine of these 16–21], no HIV-1 gene products have been found to be
patients. FGF-BP was also abundantly expressed in developing responsible for the proliferative effects of HIV-1 on renal
fetal renal tubules. Recombinant FGF-BP enhanced the mito-
epithelial or interstitial cells. Thus, it is possible thatgenic effects of bFGF in cultured human RPTEcs.
these changes may be mediated by cytokines or growthConclusions. The localization of FGF-BP in renal tubular
epithelial cells could provide a mechanism by which the activity factors released by HIV-infected or injured renal cells
of bFGF is modulated in developing and regenerating renal [22–24]. In previous studies, we have shown a significant
tubules of children. up-regulation of FGF low-affinity receptors in the kid-
neys from HIV-Tg mice [9] and HIV-infected children
with renal disease [10]. These findings suggest that bFGF
Basic fibroblast growth factor (bFGF) is a growth fac- may be sequestered from the circulation and stored in
tor that lacks a signal peptide for secretion, and it is the kidney bound to heparan sulfate proteoglycans
normally stored as an “inactive pool” in the vessel wall (HSPG) [9, 25, 26]. High levels of bFGF may lead to
the development of focal segmental glomerulosclerosis
[27, 28], and an excessive accumulation of bFGF in theKey words: pediatric renal disease, HIV nephropathy, hemolytic ure-
mic syndrome, basic fibroblast growth factor, kidney development. renal extracellular matrix can induce the tubulointersti-
tial proliferative and fibrotic lesions typical of HIVAN.Received for publication August 15, 2000
However, the mechanisms that control the release andand in revised form October 27, 2000
Accepted for publication November 10, 2000 activity of bFGF in renal tubules and glomeruli are not
clearly described.Ó 2001 by the International Society of Nephrology
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In 1991, Wu et al first described a secreted FGF bind- was 3.0 6 0.9 years. Sixty percent of these patients were
African American, 30% were Hispanic, and 10% wereing protein (FGF-BP) in a tumor cell line [29]. Subse-
quent studies in nontumorigenic cells (SW-13) demon- Caucasian. The diagnosis of HIV infection and the differ-
ent types of renal diseases was done by standard clinicalstrated that the expression of FGF-BP can mobilize and
activate bFGF and thus lead to tumor growth and angio- and pathologic criteria. The normal human fetal kidneys
were obtained at autopsy from fetuses of 19.5 to 24.0genesis of the FGF-BP–transfected cells [30]. Further-
more, in different tumor cell lines expressing high levels weeks of gestation. All pregnancies were terminated for
medical reasons not related to this study (tumor, osteo-of FGF-BP mRNA, a reduction of FGF-BP expression
using ribozymes reduced tumor growth and angiogenesis genesis imperfecta type II, complex congenital heart dis-
eases, and limb-body wall disruption sequence). All fetalof xenografts of these cells in athymic nude mice [31].
These findings suggest that FGF-BP may have a rate- kidneys showed normal glomeruli and developing tubules.
limiting role in the modulation of bFGF activity and
Cell culturestumor growth. Since we have found that renal epithelial
cells isolated from HIV-Tg mice and HIV-infected chil- Human renal proximal tubular epithelial cells (RPTEcs)
were derived from a kidney considered unsuitable fordren with renal disease synthesize and release significant
levels of bFGF into the conditioned media [9, 10, 15], it transplantation and not infected with HIV-1. Urinary
renal tubule epithelial cells (RUTEcs) were derived fromis possible that one potential mechanism through which
bFGF could be mobilized from renal cells is by binding to three different children with HIV-associated renal dis-
eases. Both RPTEc and RUTEc were isolated, ex-FGF-BP. The present study demonstrates, to our knowl-
edge for the first time, the presence and up-regulation of panded, and characterized as described previously [10,
15, 21]. Both cell types were cultured on REGM BulleKitFGF-BP in renal tubular epithelial cells (RUTEcs) from
children with HIV-associated nephropathies, HUS, other culture media from Clonetics (BioWhittaker Inc., Walk-
ersville, MD, USA). Human glomerular podoctyes wererenal diseases, and developing fetal tubules. Together with
previous studies, these findings suggest that FGF-BP may isolated from renal glomeruli derived from a kidney not
infected with HIV-1 and considered unsuitable for trans-play a relevant role modulating the release and activity
of bFGF in the renal tubulointerstitium in children with plantation. Briefly, the renal cortex was minced into
1 mm fragments and passed through a graded series ofrenal disease and during renal development.
metal sieves. The resulting material containing approxi-
mately 95% glomeruli by microscopic examination was
METHODS
incubated with collagenase (type IV; Sigma Chemical
Patients Co., St. Louis, MO, USA) at 378C for 15 minutes. Glo-
meruli were then pelleted, resuspended in culture media,This study was approved by the Institutional Review
Board from the Children’s National Medical Center. and seeded on different culture dishes as described pre-
viously [10]. Colonies of glomerular epithelial cellsForty-one renal sections obtained at autopsy or renal
biopsy from children with the following diagnosis were (GECs) were selected using cloning rings, and all other
cells that remained attached to the culture dishes wereused in this study: HIV-infected children without renal
disease (N 5 6), HIVAN (N 5 6); HIV-associated HUS discarded using a cell scraper. GECs were grown in cul-
ture media KGM2-BulleKit from Clonetics. Expanded(HIV-HUS; N 5 3), classic HUS (D 1 HUS; N 5 8),
HIV-negative children with focal and segmental glomer- colonies of GECs that showed positive immunostaining
with a monoclonal antibody against the podocyte specificulosclerosis (N 5 5), acute renal failure (ARF) caused
by pyelonephritis, sepsis or cardiac failure (N 5 3), and antigen GLEEP-1 (generously provided by Dr. Roger
Wiggins, Ann Arbor, MI, USA) and positive stainingnormal human fetal kidneys (N 5 5). Control renal sec-
tions were obtained from HIV-negative children without with an antibody against WT-1 (Dako, Carpinteria, CA,
USA) were used for the reverse transcriptase-polymer-renal diseases who died of brain tumors or other central
nervous system problems (N 5 5). Since all sections ase chain reaction (RT-PCR) studies. Human mesangial
cells were isolated from renal glomeruli as describedfrom HIV-infected children without renal disease were
obtained from autopsy material, all sections derived from previously [10, 33]. Mesangial cells showed a polygonal
shape, positive staining for F actin using Bodipy-phallaci-children with HIVAN were also obtained from autopsy
material. In a similar manner, all sections obtained from din (Molecular Probes, Eugene OR, USA), formed ridge
composed of multiple layers of cells surrounding regionsbiopsy material in each different group were compared
with each other. The preservation of the RNA in control of monolayers, and expressed a high number of angioten-
sin II type 1 receptors. Human glomerular endothelialand diseased human renal sections used in this study
was tested before with other RNA probes [32]. All fully cells were a generous gift from Dr. Carl Soderland from
the Applied Cell Biology Research Institute (Seattle,developed kidneys were from patients between the ages
of 1 month and 16 years. The mean age of the patients WA, USA). These cells were positive for expression of
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von Willbrand’s factor and were grown in the presence stained with hematoxylin. We used affinity-purified IgG
fractions (2.5 mg/mL) from a rabbit polyclonal antibodyof culture medium containing recombinant human epi-
dermal growth factor (rhEGF; 10 ng/mL), bovine brain directed against unique peptide sequence of bFGF (pro-
vided by Dr. Baird, PRIZM Pharmaceuticals, San Diegoextract, heparin (0.5 mg/mL), amphotericine B 50 (ng/
mL), gentamicin (50 mg/mL), and 5% fetal bovine serum CA, USA) [34], a monoclonal antibody against bovine
bFGF from Upstate Biotechnology (Lake Placid, NY,(FBS) from Cell Systems (Kirkland, WA, USA). All
cells were used between passages 2 and 4. USA), and affinity-purified rabbit antibodies raised
against a GST-human FGF-BP fusion protein (5 mg/mL)
Isolation of recombinant FGF-BP diluted in 2% bovine serum albumin (BSA) phosphate-
buffered saline (PBS) [31] or against the N-terminalRecombinant FGF-BP protein was produced by infect-
ing Sf-9 insect cells with a baculovirus (BAC-TO-BAC FGF-BP peptide [35]. Double staining of anti-bovine
basic FGF (type II, mouse monoclonal IgG1k (UBI)Baculovirus Expression System; GIBCO BRL, Grand
Island, NY, USA) containing the human BP1 cDNA and FGF-BP was performed by using Histostain-DSe
double-staining kit (Zymed). The specificity of the bFGF(Gen Bank #M60047; bases 197-799) flanked by six histi-
dine residues for affinity purification. Sf-9 cells were and FGF-BP antibodies has been demonstrated before
[31, 34, 35]. The specificity of FGF-BP staining in controllyzed in buffer A (6 mol/L guanidine-HCl, 0.01 mol/L
Tris-HCl, 0.1 mol/L sodium phosphate, pH 8.0) using a and diseased renal sections was tested after preabsorp-
tion of the primary antibody with a 20-fold excess of re-Dounce homogenizer and subsequent incubation on ice
for one hour. The suspension was centrifuged at 10,000 3 combinant FGF-BP. Other controls included replacing
the primary antibody with equivalent concentrations ofg for 15 minutes, and the supernatants were loaded onto a
Ni-NTA sepharose (Qiagen, Hilden, Germany) column. a polyclonal rabbit immunoglobin preparation derived
from nonimmune rabbit and omitting the first antibodies.Following a 45-minute incubation with the resin on ice, the
column was washed with buffer A, and purified FGF-BP In addition, we used the following antibodies: a biotinyl-
ated antiproliferative cell nuclear antigen (PCNA) mono-was eluted by a stepwise lowering of the pH of the elution
buffer (30 mmol/L sodium citrate, 300 mmol/L NaCl; clonal antibody (clone PC10) from Zymed, and a rabbit
anti-human Ki67 antibody from Dako at concentrationspH 8, 6.3, 5.9, 5.7, and 4.5, respectively). Purified FGF-BP
elutes in the final fraction. recommended by the manufacturers to detect proliferat-
ing cells; and biotinylated forms of Dolichos biflorus
[3H]-thymidine incorporation studies agglutinin, Peanut agglutinin, and Lotus tetragonolobus
agglutinin (50 to 80 mg/mL) from Vector LaboratoriesThe [3H]-thymidine incorporation studies in human
RPTEcs were done as described previously [9, 10]. (Burlingame, CA, USA) to identify collecting ducts, dis-
tal tubules, and proximal tubules, respectively [36]. TheBriefly, RPTEc were made quiescent for 48 hours in the
absence of serum and other growth factors and then intensity and distribution of FGF-BP staining were quan-
titated by counting the percentage of positive glomerularpulsed with bFGF (1 to 5 ng/mL; Biosource, Camarillo,
CA, USA) or control buffer in the presence and absence cells, renal cortical proximal and distal tubules, collecting
ducts, dilated tubules, or cysts stained by the FGF-BPof recombinant FGF-BP 30 ng/mL. After 24 to 48 hours,
the cells were incubated with 1 mCi/mL [3-H] thymidine antibody in 10 microscopic fields (3100) in each section.
A semiquantitative scoring system (0 to 4) was used: scorefor an additional six-hour period and processed as de-
scribed before [9]. The results were expressed in counts 0 5 0 to 5%, score 1 5 6 to 15%, score 2 5 16 to 25%,
score 3 5 26 to 50%, and score 4 5 51 to 100%. Allper minute (cpm) and confirmed by cells counts as pre-
viously described [9]. sections stained under identical conditions were com-
pared independently by two investigators.
Immunohistochemisty
Western blotsParaffin sections were cut at 4 mm and deparaffinized
and rehydrated. Renal sections were then heated twice The presence of FGF-BP was confirmed by Western blot
analysis using the ECLe Western blotting kit from Amer-for five minutes each in 0.01 mol/L sodium citrate (pH 6.0)
in a microwave oven (2450 mHz, 850 W) to augment shame (Life Science, Little Chalfont, Buckinghamshire,
UK) as described previously [11]. Briefly, cell extractsantigen retrieval. Endogenous peroxidase activity was
blocked by treating with 3% H2O2 in 100% methanol containing a known amount of protein (20 mg) were sep-
arated on denaturating, reducing 12.5% sodium dodecylfor 10 minutes. Immunostaining was performed with a
commercial streptavidin-biotin-peroxidase complex His- sulfate (SDS)-polyacrylamide gels. The electrophoresed
proteins were transferred to nitrocellulose filters by elec-tostaine SP kit (Zymed, South San Francisco, CA, USA)
according to the manufacturer’s instructions as previ- troblotting and were immunostained with specific anti-
bodies for FGF-BP (1/2000) and bFGF (1/1000) as de-ously described [10, 32]. The peroxidase substrate chro-
magen was aminoethyl carbazole. Sections were counter- scribed previously in this article. Both proteins were
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detected and quantitated using Hyperfilme ECLe films, HCl, pH 7.8) at room temperature for 15 minutes, and
the sections were incubated with antidigoxigenin anti-which exhibit a linear response to the light produced
body conjugated with alkaline phosphatase (Boehringer-from a chemiluminescence signal. The film was used for
Mannheim Biochemica) at the dilution of 1:750 for 30the densitometric analysis, and the results were expressed
minutes at 378C. Colorimetric detection with nitro bluein arbitrary optical density units.
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate
Preparation of digoxigenin-labeled human (Boehringer-Mannheim Biochemica) was then performed,
FGF-BP riboprobe and the sections were mounted in 60% glycerol and ex-
amined by light microscopy. The negative controls in-Human probe. A 790 bp human FGF-BP cDNA (Gene
cluded (1) hybridization with the sense probe, (2) RNaseBank #M60047) was subcloned into the HindIII and
A [100 mg/mL in 10 mmol/L Tris HCl, pH 8.0, 1 mmol/LXbaI sites of the pRC/CMV vector between T7 and SP6
ethylenediaminetetraacetic acid (EDTA)] pretreatmentpromoters. The vector was linearized with the restriction
before hybridization, and (3) omission of either the anti-enzymes Bgl II or Xba I and utilized as a template for the
sense RNA probe or the antidigoxigenin antibody. Posi-synthesis of DIG-labeled antisense or sense riboprobe,
tive renal structures were counted and quantitated asrespectively. For both probes, in vitro transcription reac-
described previously in this article for the immunohisto-
tions were performed with SP6 or T7 RNA polymerase chemistry studies.
in the presence of DIG-UTP by using a DIG RNA label-
ing Kit (Boehringer-Mannheim Biochemica, Mannheim, Reverse transcriptase-polymerase chain reaction
Germany). The reaction products were purified by phe- Total RNA was extracted from control and diseased
nol extraction and ethanol precipitation and stored at tissue samples or cells using the Trizol (GIBCO BRL)
2708C until use. Labeling efficiency of the riboprobe isolation technique, as directed by the manufacturer’s
was estimated by comparison with tenfold serial dilution instructions. Reverse transcription (RT) of 2 mg of total
of a digoxigenin-labeled control riboprobe and direct RNA was performed using the reverse transcription kit
detection of the labeled riboprobe with antidigoxigenin from Promega (Madison, WI, USA). The resulting first-
antibodies. Riboprobe concentrations were adjusted to strand cDNA was used as template for subsequent PCR
be equivalent on the basis of the labeling efficiency be- using the Advantage PCR Kit from Clontech (Palo Alto,
fore use in the in situ hybridization studies. CA, USA). The primers used to amplify FGF-BP were
1296 forward primer: 59-GCAAGTTTGTCACCAAAG
In situ hybridization ACC-39; BP 1622 reverse primer: 59-CTGCTTTCTCC
TTCCTGGGC-39. The b-actin gene was amplified usingTen percent neutral-buffered formalin-fixed and par-
the following primers: forward primer 59-TGCGTTACAaffin-embedded renal tissues were cut at 4 mm and floated
CCCTTTCTTGAC-39; reverse primer 59-ACTGGTCTConto 2% 3-aminopropyltriethoxysilane (APES; Sigma
AAGTCAGTGTAC-39. The PCR was performed at anChemical, St. Louis, MO, USA)-coated slides. Sections
annealing temperature of 588C for 30 cycles for FGF-BPwere heat fixed for 30 minutes at 658C and deparaffinized.
and 25 cycles for b-actin. The products were separatedAfter a 30-minute incubation in 5 mmol/L levamisole, the
on 1.2% agarose gels and stained with ethidium bromide.sections were washed in PBS and in diethyl pyrocarbon-
In each experiment, water was used as a negative controlate-treated water for 5 minutes each, and then immersed
for contamination. For quantitation, various dilutions ofin 0.2 mol/L HCl for 20 minutes. Next, the sections were
first-strand cDNA (1/5–1/40) were tested in the amplifi-deproteinized by digestion with 20 to 40 mg/mL protein-
cation reaction, and the human b-actin primers werease K (Sigma) for ten minutes at 378C, washed twice in
included in every reaction as an internal control. In ac-0.2% glycine for five minutes, and in PBS for ten minutes,
cordance to preliminary experiments, the number ofand postfixed with 1.5% paraformadehyde–1.5% glutar-
PCR cycles (30–25) were in the linear range of amplifica-aldehyde for one minute. After rinsing twice for five min-
tion for both sets of primers, FGF-BP and b-actin, re-
utes in PBS, sections were dehydrated through a graded spectively. Polymerase chain reaction (PCR) was carried
ethanol series and air dried. The sections were hybridized out with cDNA diluted to reflect approximately 0.2 mg
with the human FGF-BP RNA sense and antisense probes RNA. Finally, the PCR products in ethidium bromide
at the final concentrations of 0.1 to 0.5 ng/mL in 2 3 gels were photographed, and the densitometry values of
standard saline citrate (SSC), 10% dextran sulfate, 1 3 the amplified cDNA bands were calculated by densitom-
Denhardt’s solution, 20 mmol/L Vanadyl Ribonucleo- etry image scanning. The product yield was expressed
side Complex (GIBCO BRL, Life Technologies, Gaith- as a ratio to b-actin. Confirmation of the identity of
ersburg, MD, USA), 0.1 mol/L sodium phosphate under the products generated from the FGF-BP primers was
sealed coverslips, and incubated overnight in a moist determined by sequencing of the PCR product using
chamber at 428C. They were washed in 0.2 3 SSC and Terminator Ready Rxn Mix (Perkin Elmer, Norwalk,
then blocked with a blocking solution (50 mg/mL CT, USA) and 373 DNA Sequencer (Applied Biosys-
tems, Foster City, CA, USA).skimmed dried milk, 150 mmol/L NaCl, 100 mmol/L Tris
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Statistical analysis
Results are expressed as mean 6 SD. Differences be-
tween two groups were compared by the Student t-test.
When more than two means were compared, differences
were measured by one-way analysis of variance followed
by multiple comparisons using the Student-Neuman-
Keul test. In addition, the nonparametric Kruskal–Wallis
test was used to analyze small sample size groups (N ,
5). However, since the mean and the median of these
groups did not differ by much, results were expressed in




To determine the localization and pattern of distribu-
tion of FGF-BP in human kidneys, we performed immu-
nohistochemical studies in renal sections from HIV-
infected children with and without renal disease, as well
as in other normal control and diseased renal sections
from HIV-negative children and human fetal kidneys
(Fig. 1). As shown in Figure 1A, renal sections from fully
developed normal pediatric kidneys, normal kidneys
from HIV-infected children, and HIV-1–negative renal
sections with glomerulosclerosis showed almost undetect-
able levels of FGF-BP protein in both renal glomeruli
and tubules. Similar low levels of FGF-BP expression
were found in renal glomeruli from patients with HIVAN,
HIV-HUS, or classic HUS, despite the presence of bFGF
in glomerular basement membranes and cells (Fig. 1C).
In contrast, the expression of FGF-BP protein was sig-
nificantly increased in renal tubules from children with
renal diseases associated with tubular injury and high
levels of bFGF in the tubulointerstitium (Fig. 1C). Un-
fortunately, because of the small and variable number
of nephropathies studied, we were unable to determine
whether the expression of FGF-BP was more signifi-
cantly increased in any of these groups or whether its
b
Fig. 1. Comparison of the expression of fibroblast growth factor-bind-
ing protein (FGF-BP) protein (A) and FGF-BP mRNA (B) as well as
basic fibroblast growth factor (bFGF) protein (C) in sections from
normal and pathologically altered pediatric kidneys. Immunohisto-
chemistry (A and C) and in situ hybridization (B) were used to detect
FGF-BP or bFGF protein or mRNA, respectively (individual examples
are in Figs. 2 and 3). Control kidney, renal sections from human immu-
nodeficiency virus (HIV)-negative children without renal disease (N 5
5). Groups are defined as: HIV-normal kidney, renal sections from
HIV-infected children with no apparent renal disease (N 5 6); HIV-
associated nephropathy (N 5 6); HIV-HUS, HIV-associated hemolytic
uremic syndrome (N 5 3); classic HUS, children during the acute stages
of the diarrhea-associated HUS (N 5 8); glomerulosclerosis, HIV-
negative children with focal and segmental glomerulosclerosis (N 5 5);
ARF, acute renal failure (N 5 3); fetal kidney (N 5 5). Significant
differences relative to normal kidney sections are indicated by an aster-
isk (P , 0.05). Symbols are: (h) glomeruli; (j) tubules.
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Fig. 2. Immunohistochemistry for FGF-BP
protein and bFGF protein in pediatric renal
sections. (A and B) Representative renal sec-
tions from a child with HIVAN incubated with
the primary FGF-BP antibody (A) as de-
scribed in the Methods section or incubated
with the same antibody blocked with a 20-fold
excess of recombinant FGF-BP protein (B;
original magnification 3320). Note the local-
ization of FGF-BP (red stain) in RUTEcs. (C )
S representative renal section from a human
fetal kidney of 19 weeks gestation stained with
the FGF-BP antibody (original magnification
3200). (D) A representative renal section
from an HIV-infected child without renal dis-
ease incubated with FGF-BP antibody (origi-
nal magnification 3320). (E) A colocalization
staining of bFGF (blue color) and FGF-BP
(red color) in regenerating RUTEcs and inter-
stitium in a representative renal section from
a child who suffered a fatal clinical form of
classic (D1) HUS (original magnification
3320). (F) A colocalization staining of bFGF
(red color) and FGF-BP (dark blue color) in
the renal interstitium and tubules of a child
with HIVAN (original magnification 3320).
(G) A representative renal section from a
child with HIV-HUS, demonstrating a colo-
calization staining of FGF-BP (red stain) and
PCNA (dark blue stain) in renal tubules (orig-
inal magnification 3320). (H) A representa-
tive renal section from a child with HIVAN
demonstrating a colocalization staining of
FGF-BP (red staining) and the lectin DBA
(dark blue stain), showing the presence of
FGF-BP in renal collecting ducts (blue stain).
FGF-BP is also found in distal tubules that do
not stain with the lectin antibody.
expression was correlated with the severity of renal tubu- to bFGF, we performed colocalization studies of FGF-BP
and bFGF. These studies demonstrate a significant corre-lar damage in these cases. As shown in Figure 2, the
FGF-BP staining in renal sections with HIVAN (Fig. lation between the up-regulation of FGF-BP and the accu-
mulation of bFGF in the renal extracellular matrix sur-2A) was blocked by preincubating the primary FGF-BP
antibody with a 20-fold excess of recombinant FGF-BP rounding these renal tubules in children with classic HUS
(Fig. 2E), HIVAN (Fig. 2F), and HIV-HUS (data not(Fig. 2B). Moreover, the up-regulation of FGF-BP in
renal tubules of children with HIVAN contrasted with shown). In contrast, no staining of FGF-BP was found
in normal control human sections despite the presencethe absence of FGF-BP staining in renal sections from
HIV-infected children without renal disease (Fig. 2D). of minimal bFGF staining on the basement membrane
of the Bowman’s capsule, surrounding proximal tubules,Interestingly, renal tubules from human fetal kidneys of
approximately 19 to 24 weeks’ gestation also showed and the renal extracellular matrix (Fig. 1A). The accumu-
lation of FGF-BP and bFGF was predominately but nothigh levels of FGF-BP expression (Fig. 2C), suggesting
a role of FGF-BP during the development of renal tu- necessarily limited to human renal tubules that were un-
dergoing regenerative/proliferative changes, as estimatedbules. To determine whether the expression of FGF-BP
was up-regulated in RUTEcs located in close proximity by immunostaining using Ki67 and PCNA antibodies
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Fig. 3. In situ hybridization for FGF-BP
mRNA expression in representative pediat-
ric and fetal renal samples. (A) A control
normal renal section hybridized with the
FGF-BP antisense probe. No FGF-BP mRNA
is detected in renal tubules. (B) A renal sec-
tion from a human fetal kidney of approxi-
mately 20 weeks’ gestation hybridized with
the FGF-BP antisense probe. FGF-BP mRNA
is found in developing renal tubules (dark pur-
ple stain). (C–E ) Representative renal sec-
tions from a child with HIVAN hybridized
with the FGF-BP antisense probe (C and E,
dark purple stain) or with the FGF-BP sense
probe (D), as described in the Methods sec-
tion. (F ) A renal section from an HIV-infected
child without renal disease hybridized with
the human FGF-BP antisense probe (original
magnification A–F 3400).
(Fig. 2G). Specific staining of FGF-BP was localized pre- bules from children with HIV associated nephropathies
(Fig. 3C, D control probe, and Fig. 3E), HUS, and otherdominately to renal collecting ducts, distal tubules (Fig.
2H), and regenerating renal proximal tubules (Fig. 2A). renal diseases (Fig. 1). As shown with the expression of
FGF-BP protein, no detectable levels of FGF-BP mRNA
In situ hybridization were found in HIV-infected children without renal dis-
ease (Fig. 3F). Both FGF-BP protein and mRNA wereThe in situ hybridization studies performed in control
and diseased renal sections with a human FGF-BP RNA found in a similar location in the renal tubules from
patients with classic HUS (Fig. 2E) and in HIV-infectedprobe confirmed the results obtained by immunohisto-
chemistry. The expression of FGF-BP mRNA (Fig. 1B) patients with renal disease (Fig. 2F). These findings dem-
onstrate that the RUTEcs from HIV-infected patientsfollowed the same pattern of distribution as the FGF-BP
protein (Fig. 1A). No significant staining was detected in with renal disease locally produce FGF-BP, as opposed
to absorbing the protein from the circulation, urine, orrenal sections from control children without renal disease
(Fig. 3A). In contrast, high levels of FGF-BP mRNA renal interstitium.
The presence of FGF-BP in RUTEcs was confirmedexpression were detected in developing fetal tubules
(Fig. 3B), and in regenerating and/or injured renal tu- by Western blot studies in protein extracts from cultured
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Fig. 5. Western blot analysis for FGF-BP in urine samples from chil-
dren with renal diseases. Urine samples (10 mL) were loaded in each
gel lane and electrophoresed through a 12.5% denaturing reducing
polyacrylamide gel, processed as described in the Methods section and
immunostained with an antibody against FGF-BP (1/1000 dilution).
Lane 1, standard, 30 ng/mL human recombinant FGF-BP. Lanes 2 and
3, urine samples from two patients with HIV-HUS. Lane 4, urine sam-
ples from a patient with HIVAN. Lane 5, urine sample from a child
Fig. 4. Western blot analysis for FGF-BP in human urinary renal tubu- with ARF. Human recombinant FGF-BP protein was detected at ap-
lar epithelial cells (RUTEcs). Twenty micrograms of protein extracts proximately 34 kD. FGF-BP in the urine of these patients was detected
were loaded in the gel and electrophoresed through a 12.5% denaturing at approximately 34 kD and a weaker higher molecular weight band
polyacrylamide gel. The electrophoresed proteins were transferred to of approximately 52 kD.
nitrocellulose filters by electroblotting and were immunostained with
an antibody against FGF-BP (1/1000 dilution) [31] as described in the
Methods section. Lane 1, standard, 30 ng/mL human recombinant
FGF-BP. Lane 2, protein extracts from urinary RUTEcs derived from
a child with HIV-HUS. Human recombinant FGF-BP was detected at
approximately 34 kD. FGF-BP in urinary RUTEcs was detected at an
approximately 34 kD band, in addition to a higher molecular weight
band of approximately 52 kD.
Fig. 6. Analysis of FGF-BP expression by RT-PCR. Total RNA (2 mg)
urinary RUTEcs isolated from HIV-infected children was extracted from human RUTEcs and processed for RT-PCR as
with renal disease (Fig. 4). Using an affinity-purified rab- described in the Methods section. Different dilutions of first-strand
cDNA were used (1 5 1/40, 2 5 1/20, 3 5 1/10, 4 5 1/5), and the PCRbit antibody raised against a GST-human FGF-BP fusion
amplification process was allowed to proceed for either 30 cycles (A)
protein, we found a strong immunoreactive band at ap- or 35 cycles (B). A linear relationship between input cDNA and FGF-BP
proximately 34 kD and a higher molecular mass band amplification was noted after 30 cycles of amplification. All RT-PCR
studies for FGF-BP were done using 30 cycles of amplification.of approximately 52 kD. This higher band could also be
detected with another antibody raised against an
N-terminal FGF-BP peptide and is probably due to the
1 and 5 ng/mL of bFGF, respectively, in subconfluentformation of complexes with other proteins in RUTEcs.
RPTEc by approximately 30% (Fig. 8). Cell counts inIn the urine, we detected FGF-BP predominately as a
RPTEc followed for four days confirmed the results of the34 kD band, as well as a weaker band at approximately
[3H]-thymidine incorporation studies: control, 26,730 652 kD (Fig. 5). These findings suggest that FGF-BP is
870; FGF-BP (30 ng/mL), 28,685 6 1034; bFGF (5 ng/mL),secreted by RUTEcs into the urine. Finally, we deter-
64,564 6 1547; and FGF-BP 1 bFGF, 78,840 6 1856*;mined the expression of FGF-BP in cultured human glo-
mean 6 SD cells/cm2, respectively (*P , 0.05 when com-merular and tubular epithelial cells by RT-PCR (Figs. 6
pared with all other groups). These findings may be biolog-and 7). Figure 6 shows the linear relationship between
ically significant considering that cultured RPTEc expressinput cDNA and the FGF-BP amplification product after
significant levels of endogenous FGF-BP. Taken together,30 cycles of amplification. Figure 7 confirms the expres-
these data support a general role of FGF-BP modulatingsion of FGF-BP mRNA in cultured RUTEcs by RT-
the activity of bFGF during renal tubular growth andPCR and demonstrates that cultured glomerular podo-
regeneration (Fig. 9), and it may affect the activity of
cytes and mesangial and glomerular endothelial cells ex- bFGF in the renal interstitium as well. This function of
press almost undetectable levels of FGF-BP. FGF-BP may be particularly apparent in HIVAN and
HUS and during renal development.[3H]-thymidine incorporation studies and cell counts
The thymidine incorporation studies done in cultured
DISCUSSIONhuman RPTEc revealed that FGF-BP (30 ng/mL) alone
did not significantly affect the growth of cultured RPTEc This study describes a potential novel mechanism by
which the activity of bFGF accumulated in the renal(Fig. 8), but enhanced the growth-promoting effects of
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Fig. 7. RT-PCR studies for the FGF-BP and b-actin genes in cultured
human glomerular and renal tubular cells types. Total RNA derived
from each cell type was processed for RT-PCR studies as described in
the Methods section. (A) The 330 bp amplification products correspond-
ing to FGF-BP. (P) FGF-BP human plasmid (20 ng). Lane 1, distilled
water. Lane 2, human RPTEcs. Lane 3, urinary RUTEcs from a child
Fig. 8. [3H]-Thymidine incorporation studies in cultured human renalwith HIV-HUS (RW). Lane 4, urinary RUTEcs from a child with
proximal tubular epithelial cells (RPTEcs). The [3H]-thymidine incorpo-HIVAN (DC). Lane 5, urinary RUTEcs from a child with HIV-HUS
ration studies were done as described in the Methods section. The(BS). Lane 6, human glomerular endothelial cells. Lane 7, adult human
results represent mean 6 SD from three different experiments (N 5mesangial cells. Lane 8, human fetal mesangial cells. Lane 9, glomerular
8, each experiment). FGF-BP (30 ng/mL) alone did not affect the growthpodocytes. Lane 10, human kidney from a six-month-old child. (B) The
of RPTEc, but enhanced the growth promoting effects of 1 and 5 ng/mL550 bp amplification products for the human b-actin gene amplified
of bFGF, respectively, in subconfluent RPTEc. Symbols are: (h) controlfrom the same samples (1–10).
buffer; (j) FGF-BP; NS, nonsignificant; ***P , 0.001; **P , 0.001.
tubulointerstitum of children with renal disease may be
High concentrations of biologically active aFGF andmodulated. More specifically, we have found that the
bFGF are found in extracts of normal embryonic andproliferative changes characteristic of pediatric HIV-
adult tissues [44] as well as in tumor tissues of differentassociated nephropathies are paralleled by the accumula-
origin [3–5, 7, 41]. In a similar manner, we have foundtion of bFGF in the renal extracellular matrix and the
high levels of bFGF in the plasma and urine of HIV-up-regulation of a secreted FGF-BP, which is produced
infected children with HIVAN and HUS [10, 11]. Thesein RUTEcs and enhances the mitogenic activity of bFGF
HIV-associated renal diseases are associated with an in-in RUTEcs. Since FGF-BP is known to facilitate the
creased expression of renal HSPGs that may facilitaterelease and activity of FGFs from the extracellular matrix
the accumulation of bFGF in the kidney and the progres-[31], the localization of bFGF and FGF-BP in the kidney
sion of renal disease [9, 10].of HIV-infected children with HIVAN suggests that both
The biological activity of bFGF, however, is quenchedfactors may play a relevant role in the pathogenesis of
by its tight binding to HSPGs present in the renal extra-HIV-induced tubulointerstitial changes. These changes,
cellular matrix [41–43]. To date, it is not clearly under-however, are not exclusive of the pathogenesis of HIV-
stood how bFGF becomes solubilized and thus activatedassociated nephropathies, since other pediatric renal dis-
in the kidney. One established mechanism that can solu-eases, that is, classic HUS, and developing renal tubules
bilize bFGF from this storage site is the digestion of theshowed similar changes.
glycosaminoglycan portion of the cell attachment mole-In recent years, several studies have demonstrated
cule by heparanases [42, 45]. Indeed, peripheral bloodan important role of acidic and basic FGF during the
mononuclear cells (PBMCs) can release heparanase ac-processes of renal tubular development, growth, and re-
tivities that can in turn release active bFGF from the localgeneration [9, 37–40]. Both acidic FGF (aFGF) and
storage in the extracellular matrix [46]. Furthermore,bFGF lack a classic signal peptide for secretion, and they
proteases that can digest the protein backbone of theare not released from cells into the extracellular space
HSPG could also release FGFs from the immobilizedfollowing a classic secretory pathway [1, 41, 42]. In con-
state and thus contribute to its activation [25, 26]. Thetrast, these growth factors are deposited into the extra-
extent of the role of heparanases and/or proteases forcellular membrane of the cells and are found tightly
bound to membrane-attached HSPGs [25, 26, 42, 43]. the release of bFGF in the kidney is not clear at present.
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Fig. 9. Model explaining the potential role of
FGF-BP (BP) in the kidney. BP is produced
in RUTEcs and secreted from these cells. FGF
(for example, bFGF) is also produced in
RUTEcs and stored in the tubular basement
membrane and extracellular matrix in the re-
nal interstitium bound to heparan sulfate gly-
cosaminoglycans (HS). The secreted BP picks
up bFGF from the cell surface and/or renal
interstitium (BP 3 bFGF) and chaperones the
growth factor in an active form to bind HS
and its cognate receptor (FGF-R) on target
cells (that is, renal fibroblast and tubular epi-
thelial cells).
Our data suggest that an alternative manner to mobilize The mechanisms responsible for the proliferative
and modulate the activity of bFGF bound to RUTEcs changes and kidney enlargement characteristic of
could be via noncovalent binding to a secreted carrier HIVAN are not clearly defined. Although there is evi-
protein. Such a secreted binding protein for FGFs was dence that primary isolates from children with HIV ne-
first described by Wu et al in 1991 [29]. This protein was phropathies can infect and injure renal epithelial cells
purified from supernatants of A431 cells by virtue of its derived from HIV-infected children [21], there are no
ability to bind with high affinity to bFGF using ligand convincing studies to suggest that HIV-1 can directly
affinity chromatography with immobilized bFGF as the induce the proliferation of renal cells. Thus, it is possible
crucial step [29]. FGF-BP contains a hydrophobic signal that HIV-infected or injured cells may release cytokines
sequence and binds to aFGF and bFGF in a noncovalent, or growth factors that can simulate the proliferation of
reversible manner [29], and releases immobilized bFGF renal cells in patients with HIVAN leading to the charac-
from storage in the extracellular matrix of cultured cells teristic renal enlargement [9, 22–24]. This study demon-
that express both BP and bFGF. This mobilized bFGF strates, to our knowledge for the first time, that BP-FGF
is biologically active [30, 45]. Wu et al also demonstrated enhances the mitogenic activity of bFGF in RPTEcs.
that preincubation of bFGF with purified FGF-BP protein Although FGF-BP induced a modest increase in the mi-
protects the mitogenic activity of bFGF from inactivation togenic activity of bFGF in these cells, these results may
by proteases and acid treatment [29]. These characteris- be biologically relevant. First, cultured RPTEcs express
tics make this binding protein (FGF-BP) an excellent
BP-FGF, and therefore, cells incubated with bFGF alone
candidate carrier molecule for bFGF. In a subsequent
should also be affected by the endogenous BP-FGF pro-study, we demonstrated that the FGF-BP binding protein
duction. Second, FGF-BP protects bFGF from proteo-can support tumor growth and angiogenesis of bFGF-
lytic degradation [31], and thus, it may further enhanceexpressing, nontumorigenic SW-13 cells [30]. The expres-
the mitogenic activity of bFGF in vivo. Third, BP-FGFsion of this binding protein in cell lines that express
may also modulate the in vivo mitogenic activity of aFGFbFGF leads to a tumorigenic and angiogenic phenotype
in renal tubular cells [39, 40]. Thus, FGF-BP may play a[30]. Moreover, FGF-BP–transfected cells release the
relevant role in the development of the tubulointerstitialprotein into their media together with bFGF in a nonco-
and microcystic changes characteristic of HIVAN andvalently bound form. This released bFGF becomes acti-
other pediatric or adult renal diseases. For example,vated biologically, and the growth phenotype of cells
Morita et al have found an interesting correlation be-expressing FGF-BP can be blocked by a specific antibody
tween the expression of renal bFGF bindings sites andfor bFGF. Taken together, these studies in addition to
the development of tubulointerstitial fibrosis in biopsiesour data support the notion that the secretion of FGF-
from adult patients with several renal diseases [47]. Kuo,BP may be an important activating step for the locally
Norman, and Wilson have suggested that an autocrinestored bFGF [30] in the kidney of HIV-infected children
and other pediatric renal diseases. stimulatory loop mediated by secreted aFGF could be
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histochemical localization of basic fibroblast growth factor in renalresponsible for the increased proliferative capacity of
cell carcinoma. Biochem Biophys Res Commun 183:937–944, 1992
renal fibroblast isolated from patients with autosomal 4. Fujimoto K, Ichimori Y, Kakizoe T, et al: Increased serum levels of
basic fibroblast growth factor in patients with renal cell carcinoma.dominant polycystic kidney disease [40]. Here, we have
Biochem Biophys Res Commun 180:386–392, 1991found that the highest levels of FGF-BP in non-HIV-
5. Nguyen M, Watanabe H, Budson AE, et al: Elevated levels of
infected children were detected in patients undergoing an angiogenic peptide, basic fibroblast growth factor, in the urine
of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:the acute stages of the HUS. Interestingly, these patients
356–361, 1994also show very high levels of bFGF in the circulation
6. Whalen GF, Shing Y, Folkman J: The fate of intravenously ad-
and the kidney [10, 11]. Finally, we detected high levels ministered bFGF and the effect of heparin. Growth Factors 1:157–
164, 1989of FGF-BP in developing renal tubules from human fetal
7. Ensoli B, Gendelman R, Markham P, et al: Synergy betweenkidneys. Thus, FGF-BP may play an important dual role
basic fibroblast growth factor and HIV-1 Tat protein in induction
during renal development and in the pathogenesis of of Kaposi’s sarcoma. Nature 371:674–680, 1994
8. Xerri L, Hassoun J, Planche J, et al: Fibroblast growth factorseveral renal diseases as well. Surprisingly, no FGF-BP
gene expression in AIDS-Kaposi’s sarcoma detected by in situwas detected in glomerular podocytes or in any other
hybridization. Am J Pathol 138:9–15, 1991
glomerular cell type. bFGF is produced by glomerular 9. Ray PE, Bruggeman LA, Weeks BS, et al: bFGF and its low affinity
receptors in the pathogenesis of HIV-associated nephropathy invisceral epithelial cells, and HSPG is the predominant
transgenic mice. Kidney Int 46:759–772, 1994basement membrane protein produced by these cells
10. Ray PE, Liu XH, Lian XU, Rakusan T: Basic fibroblast growth
[48]. High levels of bFGF may induce specific changes factor in children with HIV associated HUS. Pediatr Nephrol 13:
586–593, 1999in glomerular podocytes and focal segmental glomerulo-
11. Ray PE, Onorio A, Sgromo S, et al: Novel role of basic fibroblastsclerosis [27], and several studies have suggested that
growth factor in the pathogenesis of classic hemolytic–uremic syn-
the glomerular podocytes may play a key role in the drome, in Eschericia coli 0157:H7 and Other Shiga Toxin-Produc-
ing E. Coli Strains, edited by Kaper JB, O’Brian AD, Washingtonpathogenesis of HIVAN [19, 49]. Taken together, these
D.C., American Society for Microbiology, 1998, pp 312–322findings suggest that the activity of bFGF in renal glo-
12. Rao TK, Filippone EJ, Nicastri AD, et al: Associated focal and
merular cells may be regulated by different mechanisms segmental glomerulosclerosis in the acquired immunodeficiency
syndrome. N Engl J Med 310:669–673, 1984than in renal tubular cells.
13. Pardo V, Aldana M, Colton RM, et al: Glomerular lesions inIn summary, the presence and up-regulation of FGF-BP
the acquired immunodeficiency syndrome. Ann Intern Med
in RUTEcs from children with pediatric renal diseases 101:429–434, 1984
14. D’Agati V, Suh JI, Carbone L, et al: Pathology of HIV-associatedand fetal kidneys are shown. Moreover, we found that
nephropathy: A detailed morphologic and comparative study. Kid-FGF-BP enhances the mitogenic effects of bFGF in cul-
ney Int 35:1358–1370, 1989
tured RPTEcs. When considered in the context of other 15. Ray PE, Rakusan T, Loechelt BJ, et al: Human immunodeficiency
virus (HIV)-associated nephropathy in children from the Washing-studies [29–31], these data suggest a novel mechanism
ton, D.C. area: 12 years’ experience. Semin Nephrol 18:396–405,by which the activity of FGFs could be regulated during
1998
the process of renal tubular development and regenera- 16. Dickie P, Felser J, Eckhaus M, et al: HIV-associated nephropathy
in transgenic mice expressing HIV-1 genes. Virology 185:109–119,tion. A more detailed understanding of the mechanisms
1991by which FGF-BP modulates the release and activity of
17. Kopp JB, Klotman ME, Adler SH, et al: Progressive glomerulo-
FGFs in the kidney will hopefully facilitate the develop- sclerosis and enhanced renal accumulation of basement membrane
components in mice transgenic for human immunodeficiency virusment of novel therapies to prevent the progression of
type 1 genes. Proc Natl Acad Sci USA 89:1577–1581, 1992renal tubulointerstitial lesions in children.
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